Evidence map›Paper›PMID 28786716›Full record

ArticleExpert review of clinical pharmacology2017

Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population.

Waheed Adeola Adedeji, Sharon Iyobor Igbinoba, Titilayo O Fakeye, Ibrahim Adebayo Oladosu, Fatai Adewale Fehintola, Qing Ma, Gene D Morse

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Expert review of clinical pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Genophenotypic Factors and Pharmacogenomics in Adverse Drug Reactions.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

Waheed Adeola Adedejia Department of Clinical Pharmacology , University College Hospital , Ibadan , Nigeria.
Sharon Iyobor Igbinobab Department of Clinical Pharmacy & Pharmacy Administration, Faculty of Pharmacy , Obafemi Awolowo University , Ile-Ife , Nigeria.
Titilayo O Fakeyec Department of Clinical Pharmacy & Pharmacy Administration , University of Ibadan , Ibadan , Nigeria.
Ibrahim Adebayo Oladosud Department of Chemistry , University of Ibadan , Ibadan , Nigeria.
Fatai Adewale Fehintolaa Department of Clinical Pharmacology , University College Hospital , Ibadan , Nigeria.
Qing Maf Translational Pharmacology Research Core , School of Pharmacy and Pharmaceutical Sciences, New York Center of Excellence in Bioinformatics and Life Sciences , Buffalo , NY , USA.ORCID http://orcid.org/0000-0003-0123-9913
Gene D Morsef Translational Pharmacology Research Core , School of Pharmacy and Pharmaceutical Sciences, New York Center of Excellence in Bioinformatics and Life Sciences , Buffalo , NY , USA.
University of Ibadan · NGObafemi Awolowo University · NGUniversity at Buffalo, State University of New York · USUniversity College Hospital, Ibadan · NG

Funding

University of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8M
Antiretroviral pharmacogenomics, pharmacokinetics and toxicity in neuroAIDSK08MH098794 · NIMH · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MA, QING · 2012 to 2016
$599k
NCATS NIH HHS UL1 TR001412NIMH NIH HHS K08 MH098794
6 · The paper itself

Abstract

backgroundThere is a lack of information on CYP2D6, a major metabolizing enzyme, in Africa ethnic nationalities. The objective was to determine CYP2D6 phenotype in Yoruba Nigerians using dextromethorphan (DEX).

methodA total of 89 healthy volunteers received 30 mg of DEX orally followed by blood and urine sample collection at 3-hour and over 8 h post-dose, respectively. DEX and dextrorphan (DOR) concentrations were determined using High Performance Liquid Chromatography (HPLC). The metabolic ratio (MR, DEX/DOR) were plotted for the phenotype determination.

resultsThe log MR that separated poor (PMs) from normal metabolizers (NMs) was 0.28 and 0.75 for urine and plasma, respectively. Two subjects (2.3%) identified as PMs had a mean MR of 17 and 3.2 in plasma and urine, significantly higher than that of NMs (p < .0001). A positive correlation between urine and plasma MR was noted.

conclusionThe prevalence of PMs in the Yoruba Nigerians was similar to that reported among blacks.

Indexed as

Black PeopleAdministration, OralAdultChromatography, High Pressure LiquidCytochrome P-450 CYP2D6DextromethorphanDextrorphanFemaleHumansMaleMiddle AgedNigeriaPhenotypeTime FactorsCytochrome P-450 CYP2D6DextromethorphanDextrorphanCYP2D6dextromethorphanmetabolic ratiophenotypingYoruba Nigerian

Identifiers

PMID28786716
PMCPMC6168071
OpenAlexW2743245402

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.